BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37720428)

  • 1. Tumor mutation burden in gastro-entero-pancreatic-neuroendocrine neoplasms.
    Jeong SY; Park YS; Lee J; Jang J; Jeon Y; Jung YJ; Choi D; Hong J; Kim ST
    J Gastrointest Oncol; 2023 Aug; 14(4):1707-1714. PubMed ID: 37720428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
    Masui T; Ito T; Komoto I; Uemoto S;
    BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).
    Puccini A; Poorman K; Salem ME; Soldato D; Seeber A; Goldberg RM; Shields AF; Xiu J; Battaglin F; Berger MD; Tokunaga R; Naseem M; Barzi A; Iqbal S; Zhang W; Soni S; Hwang JJ; Philip PA; Sciallero S; Korn WM; Marshall JL; Lenz HJ
    Clin Cancer Res; 2020 Nov; 26(22):5943-5951. PubMed ID: 32883742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant Expression of Long Non Coding RNA HOTAIR and De-Regulation of the Paralogous 13 HOX Genes Are Strongly Associated with Aggressive Behavior of Gastro-Entero-Pancreatic Neuroendocrine Tumors.
    Di Mauro A; Scognamiglio G; Aquino G; Cerrone M; Liguori G; Clemente O; Di Bonito M; Cantile M; Botti G; Tafuto S; Tatangelo F
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma.
    Li MX; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Zhang XF; Pawlik TM
    J Surg Oncol; 2022 Sep; 126(4):689-697. PubMed ID: 35616186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An 11-year retrospective study: clinicopathological and survival analysis of gastro-entero-pancreatic neuroendocrine neoplasm.
    Liu H; Xie R; Zhao Z; Xu D; Yang K; Ding M; Tan D; Liao W; Han X; Zhang J; Shen D; Yuan J; Xu Z; Fei J
    Medicine (Baltimore); 2020 Aug; 99(33):e21682. PubMed ID: 32872039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias.
    Albers MB; Almquist M; Bergenfelz A; Nordenström E
    Langenbecks Arch Surg; 2020 Mar; 405(2):137-143. PubMed ID: 32291468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms.
    Holmager P; Langer SW; Kjaer A; Ringholm L; Garbyal RS; Pommergaard HC; Hansen CP; Federspiel B; Andreassen M; Knigge U
    Curr Treat Options Oncol; 2022 Jun; 23(6):806-817. PubMed ID: 35362798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endoscopic techniques for diagnosis and treatment of gastro-entero-pancreatic neuroendocrine neoplasms: Where we are.
    Rossi RE; Elvevi A; Gallo C; Palermo A; Invernizzi P; Massironi S
    World J Gastroenterol; 2022 Jul; 28(26):3258-3273. PubMed ID: 36051341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological and molecular profile of grade 3 gastroenteropancreatic neuroendocrine neoplasms.
    Taboada R; Claro L; Felismino T; de Jesus VH; Barros M; Riechelmann RP
    J Neuroendocrinol; 2022 Apr; 34(4):e13099. PubMed ID: 35174558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms.
    Elvebakken H; Hjortland GO; Garresori H; Andresen PA; Janssen EAM; Vintermyr OK; Lothe IMB; Sorbye H
    J Neuroendocrinol; 2023 Apr; 35(4):e13256. PubMed ID: 37017614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digestive Neuroendocrine Tumor Distribution and Characteristics According to the 2010 WHO Classification: a Single Institution Experience in Lebanon.
    Kourie HR; Ghorra C; Rassy M; Kesserouani C; Kattan J
    Asian Pac J Cancer Prev; 2016; 17(5):2679-81. PubMed ID: 27268650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
    Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
    Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms.
    Angerilli V; Sabella G; Simbolo M; Lagano V; Centonze G; Gentili M; Mangogna A; Coppa J; Munari G; Businello G; Borga C; Schiavi F; Pusceddu S; Leporati R; Oldani S; Fassan M; Milione M
    Br J Cancer; 2024 May; ():. PubMed ID: 38729995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of primary site and pathology on 903 patients with neuroendocrine neoplasms].
    Qiu X; Liu M; Liu Q; Yang Z; Liu J; Meng F; Wang Z; Shi Y; Liu L; Zhang P; Luo J; Tan H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):993-996. PubMed ID: 28900988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
    Zheng M; Li Y; Li T; Zhang L; Zhou L
    Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
    Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
    Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic role and prognostic value of tumor markers in high-grade gastro-enteropancreatic neuroendocrine neoplasms.
    Gao C; Fan Z; Yang J; Shi M; Li Y; Zhan H
    Pancreatology; 2023 Mar; 23(2):204-212. PubMed ID: 36710224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.